Fingerprint
Dive into the research topics of 'A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C. Bendell, Milind Javle, Tanios S. Bekaii-Saab, Richard S. Finn, Zev A. Wainberg, Daniel A. Laheru, Colin D. Weekes, Benjamin R. Tan, Gazala N. Khan, Mark M. Zalupski, Jeffrey R. Infante, Suzanne Jones, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Renae E. Chavira, Janna L. Christy-Bittel, Emma Barrett, Amita Patnaik
Research output: Contribution to journal › Article › peer-review
51
Scopus
citations